Clinical Trials - January 27, 2026
Takeda’s zasocitinib meets primary and secondary endpoints in Phase 3 study
The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).
Clinical Trials - January 27, 2026
DexTech Medical’s myeloma study, completed at the end of February
The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.
Biotech Business - January 26, 2026
Leqembi Iqlik supplemental BLA granted Priority Review by FDA
BioArctic’s partner Eisai has announced that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting dose has been granted Priority Review by the US Food and Drug Administration (FDA).
In a new job - January 23, 2026
Abera Bioscience strengthens its team
The company is in an intensive development phase in which several vaccine candidates are being advanced in parallel towards clinical development. To ensure continued high execution capacity and long-term competence, the company is now strengthening its organisation through recruitment.
Collaboration - January 23, 2026
Women in Life Science Denmark expands Nordic footprint
Women in Life Science Denmark (WiLD) has announced the launch of WiLD Finland.
Biotech Award - January 23, 2026
Mavatar launches Rare Disease Discovery Award
The aim of the initiative is to strengthen research in rare diseases where access to data and analytical tools remains limited.
